The following article is a part of conference coverage from the 2019 Advances in Inflammatory Bowel Diseases (AIBD) Meeting, being held in Orlando, Florida. The team at MPR will be reporting on the latest news and research conducted by leading experts gastroenterology. Check back for more from the 2019 AIBD Meeting.

According to new data presented at the 2019 AIBD Annual Meeting in Orlando, FL, over 1 in 5 patients with inflammatory bowel disease (IBD) should have started treatment with an advanced systemic therapy earlier in their disease.

To better understand the timing of initiation of biologic and Janus kinase inhibitor (JAK) therapies in IBD, study authors conducted a retrospective chart review using patient charts collected from 219 US gastroenterologists between May and June 2019. The analysis included 1006 patients diagnosed with either ulcerative colitis (UC) or Crohn disease (CD).

Gastroenterologists reported that among the patient charts reviewed, 23% of UC patients and 25% of CD patients should have been started on biologic or JAK therapy earlier than they were. The majority of conversations related to initiation of advanced systemic treatment were reported to be initiated by physicians (88%), and on average, patients requested treatment 4.7 months following these conversations. 

Related Articles

As for patients’ views on starting therapy, most reported feeling excited and motivated (36%) or relieved (27%), however anxiety over treatment was reported in 22% of patients. Compared with ustekinumab, vedolizumab, adalimumab, infliximab, golimumab, or certolizumab, patients initiated on tofacitinib reported more excitement and motivation.

“With increased evidence of the success of early and aggressive use of biologics or JAKs for treatment of IBD, it is important for gastroenterologists to begin having discussions with their patients at the first sign of necessity,” the study authors concluded. 


Price L, Robinson J; Patient Perspective and Timing of First-Line Advanced Systemic Treatments in IBD, Results from a National Chart Audit. Presented at the 2019 AIBD Annual Meeting on December 12-14 2019 in Orlando, FL.